Literature DB >> 16820365

Treatment of chronic heart failure: a comparison between the major guidelines.

John McMurray1, Karl Swedberg.   

Abstract

Because of rapid advances in the treatment of chronic heart failure, four important guidelines, including those from the European Society of Cardiology, have recently been updated. This review compares and contrasts the levels of evidence and classes of recommendation given to each of the key pharmacological and device therapies advocated by these guidelines. Possible explanations for discrepancies between the guidelines are discussed. Future approaches that might clarify the grade of evidence allocated and class of recommendation made are also described.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820365     DOI: 10.1093/eurheartj/ehl123

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

1.  Prevalence of Cheyne-Stokes respiration in modern treated congestive heart failure.

Authors:  Gerrit Hagenah; Dennis Beil
Journal:  Sleep Breath       Date:  2008-09-13       Impact factor: 2.816

2.  Barriers to physician adherence to nonsteroidal anti-inflammatory drug guidelines: a qualitative study.

Authors:  J M Cavazos; A D Naik; A Woofter; N S Abraham
Journal:  Aliment Pharmacol Ther       Date:  2008-09-15       Impact factor: 8.171

Review 3.  Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.

Authors:  Li-jun Hu; Yun-qing Chen; Song-bai Deng; Jian-lin Du; Qiang She
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

4.  Tools for assessing the content of guidelines are needed to enable their effective use--a systematic comparison.

Authors:  Michaela Eikermann; Nicole Holzmann; Ulrich Siering; Alric Rüther
Journal:  BMC Res Notes       Date:  2014-11-26

Review 5.  Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Hai-Ha Le; Chadia El-Khatib; Margaux Mombled; Frédéric Guitarian; Muaamar Al-Gobari; Mor Fall; Perrine Janiaud; Ivanny Marchant; Michel Cucherat; Théodora Bejan-Angoulvant; François Gueyffier
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

6.  The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.

Authors:  Hui Pei; Wei Wang; Di Zhao; Lei Wang; Guo-Hai Su; Zhuo Zhao
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

7.  Nuclear receptor subfamily 4 group A member 2 inhibits activation of ERK signaling and cell growth in response to β-adrenergic stimulation in adult rat cardiomyocytes.

Authors:  Sadia Ashraf; Yassmin K Hegazy; Romain Harmancey
Journal:  Am J Physiol Cell Physiol       Date:  2019-06-12       Impact factor: 4.249

8.  How evidence-based are the recommendations in evidence-based guidelines?

Authors:  Finlay A McAlister; Sean van Diepen; Rajdeep S Padwal; Jeffrey A Johnson; Sumit R Majumdar
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

Review 9.  Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence.

Authors:  Toshikazu D Tanaka; Mitsuaki Sawano; Ravi Ramani; Mark Friedman; Shun Kohsaka
Journal:  ESC Heart Fail       Date:  2018-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.